Gliclazide Enhances Exercise Performance and Recovery of Muscle Strength in Healthy Trained Individuals: A Randomized Controlled Trial.

Gliclazide significantly improved total volume-load in both bench press and squat exercises compared to placebo.

• Bench press total volume-load improved by 23.3% (p < 0.001)
• Squat total volume-load improved by 23.2% (p < 0.001)
• Volume-load was calculated as number of repetitions multiplied by 80% of one-repetition maximum
• Exercise sessions consisted of four sets at 80% 1-RM across three consecutive sessions

Gliclazide improved range of motion at 24-48 hours post-exercise in both shoulder and knee joints.

• Shoulder ROM improved by 1.1% (p < 0.001)
• Knee ROM improved by 1.6% (p = 0.004)
• Improvements were observed in the 24-48h post-exercise recovery window

Gliclazide reduced markers of muscle damage (CK-MM and LDH) during the 24-48h post-exercise recovery period.

• Creatine kinase MM (CK-MM) was reduced by 13.2% (p < 0.001)
• Lactate dehydrogenase (LDH) was reduced by 12.8% (p < 0.001)
• These markers were assessed as indicators of exercise-induced muscle damage

Gliclazide reduced pro-inflammatory cytokines TNF-α and IL-6 following exercise.

• TNF-α was reduced by 17.4% (p < 0.001)
• IL-6 was reduced by 5.3% (p < 0.001)
• Reductions were observed in the 24-48h post-exercise period

Gliclazide improved subjective measures of perceived muscle soreness and recovery scores.

• Perceived muscle soreness was reduced by 17.7% (p < 0.001)
• Recovery scores improved by 32.5% (p = 0.001)
• These outcomes were assessed during the 24-48h post-exercise recovery period

Hypoglycemia events occurred in 3 participants (approximately 7%) in the gliclazide group.

• 3 out of 44 participants in the gliclazide group experienced hypoglycemia events
• This represents approximately 7% of subjects
• Gliclazide MR was administered at a dose of 90 mg, 8 hours before exercise sessions
• Participants were healthy strength-trained men without diabetes

The study was a randomized, double-blind, placebo-controlled crossover clinical trial in 44 strength-trained men.

• 44 strength-trained men were enrolled
• Participants were allocated to gliclazide modified release (MR) 90 mg or placebo in a crossover design
• Drug was administered 8 hours before exercise sessions
• Three consecutive sessions of strength exercise were performed per condition
• Trial registered at ClinicalTrials.gov as NCT04443777